anzu-cel — Topline data
in 2026
Pre-specified interim and final data analyses remain expected to be triggered in 2026 upon the occurrence of a defined number of events for PFS (progressive disease or death).Source filing
IMTX biotech catalysts & pipeline
IMMATICS NV · Data as of 2026-09-08
Upcoming catalysts
IMA203CD8 — Regulatory decision
2026
Determination of recommended phase 2 dose (RP2D) remains expected in 2026Source filing
IMA203CD8 — Topline data
H2 2026
Updated data from the ongoing study, including durability follow-up at the RP2D, are planned for presentation in the second half of 2026.Source filing
IMA402 — Initial data
2H 2026
RP2D determination and Phase 1 clinical data update with focus on melanoma and gynecologic cancers treated with IMA402 monotherapy and combination with immune checkpoint inhibitor planned for 2H 2026Source filing
anzu - cel — NDA/BLA submission
1H 2027
□ BLA submission: 1H 2027Source filing
anzu-cel — NDA/BLA submission
H1 2027
The Company continues to expect BLA submission in the first half of 2027 and commercial launch of anzu-cel in the second half of 2027.Source filing
anzutresgene autoleucel — Topline data
H1 2027
The Company expects to disclose topline data from the final PFS analysis in the first half of 2027, followed by a BLA submission in 2027.Source filing
anzutresgene autoleucel (anzu-cel, IMA203) — NDA/BLA submission
1H 2027
Findings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027Source filing
IMA401 — Topline data
2027
First data from the IMA401/IMA402 combination cohort are expected in 2027.Source filing